{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-005155","form_type":"8-K","ticker":"JSPR","cik":"0001788028","company_name":"Jasper Therapeutics, Inc.","filed_at":"2023-01-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.550416+00:00","generated_at":"2026-06-20T09:37:48.203448+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Jasper Therapeutics prices $90M public offering of 60M shares at $1.50 per share","bullets":["Offering of 60M shares of common stock at $1.50/share; gross proceeds ~$90M before expenses.","Underwriters granted 30-day option to purchase up to 9M additional shares at same price.","Closing expected on or about Jan 27, 2023; proceeds for general corporate purposes.","Directors and executive officers subject to lock-up agreements until April 25, 2023.","Credit Suisse and William Blair act as active book-running managers; Oppenheimer as passive."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-005155","json":"https://secwatch.observer/filing/0001213900-23-005155.json","markdown":"https://secwatch.observer/filing/0001213900-23-005155.md","text":"https://secwatch.observer/filing/0001213900-23-005155.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1788028/000121390023005155/0001213900-23-005155-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1788028/000121390023005155/ea172170-8k_jasper.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T09:37:48.203448+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2d1a26f116e1cc82e316f2039548366ae8e33d4f","claim":"Jasper Therapeutics, Inc. entered into Underwriting Agreement with Credit Suisse Securities (USA) LLC, William Blair & Company, L.L.C. and Oppenheimer & Co. Inc. valued at approximately $90 million (effective 2023-01-25).","evidence_excerpt":"On January 25, 2023, Jasper Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Credit Suisse Securities (USA) LLC, William Blair & Company, L.L.C. and Oppenheimer & Co. Inc., as the representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 60,000,000 shares of the Company’s voting common stock, $0.0001 par value per share (“Common Stock”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390023005155/0001213900-23-005155-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Credit Suisse Securities (USA) LLC, William Blair & Company, L.L.C. and Oppenheimer & Co. Inc."},{"label":"Value","value":"approximately $90 million"},{"label":"Effective","value":"2023-01-25"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}